Search results for Eldelumab

Eldelumab, Abbexa, abx831280

Eldelumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CXCL10, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

Eldelumab ELISA Kit, ProteoGenix, KPTX139

Description of Eldelumab ELISA Kit Introduction Eldelumab is a monoclonal antibody that has been developed as a therapeutic agent for the treatment of inflammatory diseases. It works by targeting a specific protein called interleukin-6 (IL-6), which is known to play a key role in the development and progression of various inflammatory conditions. The Eldelumab ELISA Kit is a highly sensitive and specific tool that is used for the quantitative measurement of Eldelumab in biological samples. In this article, we will discuss the structure, activity, and applications of the Eldelumab ELISA Kit. Structure of Eldelumab Eldelumab is a humanized monoclonal antibody that is produced by recombinant DNA technology. It consists of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the target protein, IL-6. The constant regions provide stability and effector functions to the antibody. The Eldelumab ELISA Kit utilizes specific antibodies that are designed to recognize and bind to the unique structure of Eldelumab, allowing for its detection and quantification in biological samples. Activity of Eldelumab Eldelumab works by binding to IL-6 and preventing it from interacting with its receptor, thus inhibiting its pro-inflammatory effects. IL-6 is a cytokine that is produced by various cells in the body in response to inflammation. It plays a crucial role in the immune response, but excessive levels of IL-6 have been linked to the development of chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. By blocking the activity of IL-6, Eldelumab helps to reduce inflammation and alleviate the symptoms of these diseases. Application of Eldelumab ELISA Kit The Eldelumab ELISA Kit is primarily used for the quantitative measurement of Eldelumab in serum or plasma samples. It is a valuable tool for researchers and clinicians who are studying the pharmacokinetics and pharmacodynamics of Eldelumab and its effects on IL-6 levels. The kit is also used in clinical trials to monitor the efficacy of Eldelumab treatment in patients with inflammatory diseases. Additionally, the Eldelumab ELISA Kit can be used to assess the presence of anti-drug antibodies (ADAs) in patients receiving Eldelumab therapy. ADAs can potentially interfere with the activity of Eldelumab and may impact its effectiveness in treating inflammatory conditions. Advantages of Eldelumab ELISA Kit The Eldelumab ELISA Kit offers several advantages over other methods of detecting and quantifying Eldelumab. It is a highly sensitive and specific assay, with a lower limit of detection of 0.1 ng/mL. It also has a wide dynamic range, allowing for the measurement of both low and high levels of Eldelumab in biological samples. The kit is easy to use and provides rapid results, making it a convenient tool for researchers and clinicians. Furthermore, the Eldelumab ELISA Kit has been validated for use with multiple sample types, including serum, plasma, and cell culture supernatants. Conclusion In summary, the Eldelumab ELISA Kit is a valuable tool for the detection and quantification of Eldelumab in biological samples. Its high sensitivity and specificity make it a reliable method for monitoring Eldelumab levels in patients receiving treatment for inflammatory diseases. The kit’s ease of use and rapid results make it a convenient option for researchers and clinicians. With the increasing use of Eldelumab as a therapeutic agent, the Eldelumab ELISA Kit will continue to play a crucial role in the development and evaluation of this promising treatment.

Eldelumab ELISA Kit, Abbexa, abx395028

Eldelumab ELISA Kit is a quantitative ELISA kit for detection of Eldelumab.Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.

Eldelumab Biosimilar - Research Grade, ichor.bio, ICH5146

Detects human CXCL10

Research Grade Eldelumab (HY524016), abinScience, HY524016